Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN

NCT03955445 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

225

Enrollment

INDUSTRY

Sponsor class

Conditions

C3 Glomerulopathy
Immune-complex-membranoproliferative Glomerulonephritis

Interventions

DRUG: LNP023

Sponsor

Novartis Pharmaceuticals